Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

Platinum drugs-related safety profile: The latest five-year analysis from FDA adverse event reporting system data

BackgroundWith the widespread application of platinum drugs in antitumor therapy, the incidence of platinum drug adverse events (ADEs) is always severe. This study aimed to explore the adverse event signals of Cisplatin, Carboplatin and Oxaliplatin, three widely used platinum-containing drugs, and t...

Full description

Bibliographic Details
Main Authors: Guowen Feng, Xiaodan Zhou, Jia Chen, Dan Li, Li Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
platinum drugs
FAERS
adverse event
date mining
ADE signals
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1012093/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1012093/full

Similar Items